SynthesisBritish journal of cancer2025
Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Synthesis in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLocally advanced nasopharyngeal carcinoma (LA-NPC) has a heterogeneous prognosis, with approximately one-fourth of patients experiencing poor outcomes. Studies have explored the application of induction chemoimmunotherapy followed by chemoradiotherapy, but its efficacy was controversial.
methodsThe protocol was registered in the Prospective Register of Systematic Reviews (PROSPERO, CRD42024619387). The primary outcome measures were objective response rate (ORR), complete response rate (CRR), and the incidence of treatment-related adverse events (TRAEs). Meta-analysis was performed using Cochrane Collaboration Review Manager 5.4.1 and Meta-Analyst Beta 3.13 statistical software.
resultsThe meta-analysis involving 1680 patients with LA-NPC from 7 studies showed that the induction chemoimmunotherapy group had significantly better ORR (odds ratio[OR] = 2.03, 95% confidence interval [CI]:1.44-2.86, P < 0.01), and CRR (OR = 2.61, 95% CI:1.55-4.38, P < 0.01) than the induction chemotherapy group. The pooled ORR and CRR of induction chemoimmunotherapy were 92.7% (95% CI: 90.7-94.7%) and 24.3% (95% CI: 15.2-33.6%), respectively. There was no significant difference of TRAEs between induction chemotherapy group and induction chemoimmunotherapy group (OR = 1.13; 95% CI: 0.92-1.39, P = 0.23).
conclusionsInduction chemoimmunotherapy could be a promising induction treatment option for LA-NPC patients, improving ORR and CRR with an acceptable safety profile. However, due to limitations in this meta-analysis, further large-scale, well-designed clinical trials are required to validate these results and optimise treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.